Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,901–3,000 of 10,906
Measuring and Promoting SARS-CoV-2 Vaccine Equity: Development of a COVID-19 Vaccine Equity Index
Pressman, A. R., Lockhart, S. H., Shen, Z., & Azar, K. M. J. (2021) · Health Equity · doi:10.1089/heq.2021.0047 · Cited by 23
Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 25
COVID-19 vaccine strategies for Aotearoa New Zealand: a mathematical modelling study
Nguyen, T., Adnan, M., Nguyen, B. P., de Ligt, J., Geoghegan, J. L., Dean, R. A., Jefferies, S., Baker, M. G., Seah, W. K. G., Sporle, A. A., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100256 · Cited by 29
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis
Xu, W., Ren, W., Wu, T., Wang, Q., Luo, M., Yi, Y., & Li, J. (2023) · Vaccines · doi:10.3390/vaccines11061118 · Cited by 31
Immune interference in effectiveness of influenza and COVID-19 vaccination
Xie, Y., Tian, X., Zhang, X., Yao, H., & Wu, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167214 · Cited by 31
COVID-19 Vaccines in Older Adults
Liang, C., Lee, W., Peng, L., Meng, L., Hsiao, F., & Chen, L. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.03.006 · Cited by 28
Gronbeck, C., & Grant-Kels, J. M. (2021) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2021.05.027 · Cited by 27
Kim, S. Y. (2022) · Life Cycle · doi:10.54724/lc.2022.e2 · Cited by 29
Altomare, C. G., Adelsberg, D. C., Carreño, J. M., Sapse, I. A., Amanat, F., Ellebedy, A. H., Simon, V. R., Krammer, F., & Bajic, G. (2022) · mBio · doi:10.1128/mbio.03580-21 · Cited by 24
Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science
Saag, M. S. (2022) · Physiological Reviews · doi:10.1152/physrev.00010.2022 · Cited by 30
Karim, F., Riou, C., Bernstein, M. P., Jule, Z., Lustig, G., van Graan, S., Keeton, R., Upton, J., Ganga, Y., Khan, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46673-2 · Cited by 31
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 26
Wang, X., Chen, X., Tan, J., Yue, S., Zhou, R., Xu, Y., Lin, Y., Yang, Y., Zhou, Y. W., Deng, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.035 · Cited by 27
Fritsche, L. G., Jin, W., Admon, A. J., & Mukherjee, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041328 · Cited by 26
Hernández‐Bernal, F., Ricardo-Cobas, M. C., Martín‐Bauta, Y., Rodríguez-Martínez, E., Urrutia-Pérez, K., Urrutia-Pérez, K., Quintana-Guerra, J., Rodríguez, Z. N., Piñera-Martínez, M., Rodríguez‐Reinoso, J. L., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100497 · Cited by 40
Kaur, U., Bala, S., Joshi, A. U., Reddy, N. T. S., Japur, C., Chauhan, M., Pedapanga, N., Kumar, S., Mukherjee, A., Mishra, V. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10071153 · Cited by 26
A model framework for projecting the prevalence and impact of Long-COVID in the UK
Martin, C., Luteijn, M., Letton, W., Robertson, J., & McDonald, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260843 · Cited by 23
COVID-19 Vaccination for Persons with Parkinson’s Disease: Light at the End of the Tunnel?
Bloem, B. R., Trenkwalder, C., Sánchez‐Ferro, Á., Kalia, L. V., Alcalay, R. N., Chiang, H., Kang, U. J., Goetz, C. G., Brundin, P., & Papa, S. M. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212573 · Cited by 28
Chi, W.-Y., Hu, Y., Huang, H., Kuo, H., Lin, S., Kuo, C.-T. J., Tao, J., Fan, D., Huang, Y.-M., Wu, A. A., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01082-x · Cited by 30
Ge, X., He, Z., Yang, H., Pan, X., Yan, L., Shi, Y., Chen, Y., & Liu, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113906 · Cited by 29
Alagoz, O., Sethi, A., Patterson, B., et al. (2021) · medRxiv · doi:10.1101/2021.03.22.21254131 · Cited by 36
Boix‐Besora, A., Lorenzo, E., Lavado‐García, J., Gòdia, F., & Cervera, L. (2022) · Vaccines · doi:10.3390/vaccines10020250 · Cited by 30
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 28
Liao, Y., Zhang, Y., Zhao, H., Pu, J., Zhao, Z., Li, D., Fan, S., Yu, L., Xu, X., Wang, L., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1937328 · Cited by 27
Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
Akiyama, H., Kakiuchi, S., Rikitake, J., et al. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01245 · Cited by 25
Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy
Chen, Z., Gao, X., & Yu, D. (2022) · View · doi:10.1002/viw.20200103 · Cited by 34
Discovery of All- d -Peptide Inhibitors of SARS-CoV-2 3C-like Protease
Eberle, R. J., Sevenich, M. M., Gering, I., Scharbert, L., Strodel, B., Lakomek, N., Santur, K., Mohrlüder, J., Coronado, M. A., & Willbold, D. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00735 · Cited by 25
Lenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 28
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · eLife · doi:10.7554/elife.103690 · Cited by 33
“The immunization campaign was launched on December 21, 2020, with the BNT162b2 vaccine ( Polack et al., 2020 ), and 3 months later, the mRNA-1273 vaccine ( Baden et al., 2021 ) was added.”
Paramithiotis, E., Sugden, S., Papp, E., Bonhomme, M., Chermak, T., Crawford, S. Y., Demetriades, S. Z., Galdos, G., Lambert, B. L., Mattison, J. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880784 · Cited by 28
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N. A., Allen, M., Antony, J., Asante, K. P., Bhate, A. S., Beresnev, T. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00263-1 · Cited by 44
Self-citationArtificial intelligence-guided design of lipid nanoparticles for mRNA delivery
Su, K., Qiu, J., Xu, T., & Liu, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.11.029 · Cited by 48
de Sousa, I. P., Wallace, Z. S., Cavalcante, S. C., Ribeiro, M. P. F., Silva, J. A. B. M., Cavalcante, R. C. M., Scheuermann, R. H., & Palatnik, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-21207-2 · Cited by 29
Uaprasert, N., Pitakkitnukun, P., Tangcheewinsirikul, N., Chiasakul, T., & Rojnuckarin, P. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00776-5 · Cited by 27
Numbers of spontaneous reports: How to use and interpret?
Kant, A. C., van Hunsel, F. P. A. M., & van Puijenbroek, E. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15024 · Cited by 25
Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes
Scoccimarro, D., Panichi, L., Ragghianti, B., Silverii, G. A., Mannucci, E., & Monami, M. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.002 · Cited by 25
Mason, A. E., Kasl, P., Hartogensis, W., Natale, J. L., Dilchert, S., Dasgupta, S., Purawat, S., Chowdhary, A., Anglo, C., Veasna, D., et al. (2022) · Vaccines · doi:10.3390/vaccines10020264 · Cited by 27
Dombrádi, V., Joó, T., Palla, G., Pollner, P., & Belicza, É. (2021) · BMC Public Health · doi:10.1186/s12889-021-12386-0 · Cited by 30
Li, R., Zhao, Y., Fan, H., Zhou, H., Yin, S., Zhang, Q., Jin, M., Liu, G. L., & Huang, L. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202306145 · Cited by 26
Self-citationBreakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients
Mazuecos, A., Villanego, F., Zárraga, S., López, V., Oppenheimer, F., Llinàs-Mallol, L., Hernández, A. M. G., Rivas, A., Ruiz-Fuentes, M. C., Toapanta, N., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004119 · Cited by 30
Al‐Sadeq, D. W., Shurrab, F. M., Ismail, A., Amanullah, F. H., Thomas, S., Al-Dewik, N. I. E., Yassine, H. M., Rahim, H. F. A., Abu-Raddad, L. J., & Nasrallah, G. K. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab190 · Cited by 23
Zamani, P., Mashreghi, M., Bazaz, M. R., Zargari, S., Alizadeh, F. L., Dorrigiv, M., Abdoli, A., Aminianfar, H., Hatamipour, M., Zarqi, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.025 · Cited by 26
Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 32
Viral genome sequencing methods: benefits and pitfalls of current approaches
Jansz, N., & Faulkner, G. J. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231322 · Cited by 31
Widman, A. J., Cohen, B., Park, V., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7048 · Cited by 24
Myocarditis following COVID-19 mRNA vaccination
Parmar, K., Mekraksakit, P., Rio‐Pertuz, G. D., Sethi, P., Motes, A., Hughes, M. L., Wischmeyer, J., Carbajal, L., & Sosa, E. A. (2021) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2021.1990743 · Cited by 26
SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models
Kanimozhi, G., Bharathiraja, P., Pawar, C. S., Khan, H. A., Alrokayan, S., & Prasad, N. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638334 · Cited by 26
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
Li, J., Liu, Q., Liu, J., Fang, Z., Luo, L., Li, S., Lei, Y., Li, Z., Jin, J., Xie, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111807 · Cited by 25
Sato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.006 · Cited by 28
Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles
Nakamura, T., Nakade, T., Sato, Y., & Harashima, H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122810 · Cited by 25
Hajji, Y. A., Taylor, H., Starkey, T., Lee, L. Y. W., & Tilby, M. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01951-y · Cited by 28
Tu, Y., Hayat, T., Hobiny, A. D., & Meng, X. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.02.002 · Cited by 27
Specker, C., Aries, P. M., Braun, J., Burmester, G. R., Fischer‐Betz, R., Hasseli, R., Holle, J. U., Hoyer, B. F., Iking‐Konert, C., Krause, A., et al. (2021) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-021-01055-7 · Cited by 28
Chen, C., Lai, C.-C., Luh, D., Chuang, S., Yang, K., Yeh, Y., Yen, A. M., Chang, K., Chang, R., & Chen, S. L. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.022 · Cited by 28
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 27
Zarębska‐Michaluk, D., Hu, C., Brzdęk, M., Flisiak, R., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10081223 · Cited by 24
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study
Ferrara, F., Mancaniello, C., Varriale, A., Sorrentino, S., Zovi, A., Nava, E., Trama, U., Boccellino, M., & Vitiello, A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01216-9 · Cited by 26
Nomah, D. K., Reyes‐Urueña, J., Llibre, J. M., Ambrosioni, J., Ganem, F., Miró, J. M., & Casabona, J. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00579-6 · Cited by 26
Galindo, R. A. R., Chow, H., & Rongkavilit, C. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.05.004 · Cited by 31
Paternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 26
Humoral response to mRNA ‐based COVID ‐19 vaccine in patients with myeloid malignancies
Mori, A., Onozawa, M., Tsukamoto, S., Ishio, T., Yokoyama, E., Izumiyama, K., Saito, M., Muraki, H., Morioka, M., Teshima, T., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18138 · Cited by 23
Nordström, P., Ballin, M., & Nordström, A. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000584 · Cited by 24
A potential association between COVID-19 vaccination and development of Alzheimer’s disease
Roh, J. H., Jung, I., Suh, Y., & Kim, M. H. (2024) · QJM · doi:10.1093/qjmed/hcae103 · Cited by 28
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC
Rodeghiero, F. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.032 · Cited by 24
Rodríguez‐Espinosa, D., Montagud‐Marrahí, E., Cacho, J., Arana, C., Taurizano, N., Hermida, E., Risco-Zevallos, J. D., Casals, J., Rosario, A., Cuadrado‐Payán, E., et al. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01257-5 · Cited by 24
Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review
Asghar, N., Mumtaz, H., Syed, A. A., Eqbal, F., Maharjan, R., Bamboria, A., & Shrestha, M. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2068331 · Cited by 26
Systemic sclerosis in the time of COVID-19
Hoffmann‐Vold, A., Distler, O., Bruni, C., Denton, C. P., de Vries-Bouwstra, J. K., Matucci‐Cerinic, M., Vonk, M. C., & Gabrielli, A. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00130-8 · Cited by 31
Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid ProdrugsPreprint
Schooley, R. T., Carlin, A. F., Beadle, J. R., Valiaeva, N., Zhang, X.-Q., Clark, A. E., McMillan, R. E., Leibel, S. L., McVicar, R. N., Xie, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269159 · Cited by 24
Mouri, M., Imamura, M., Suzuki, S., Kawasaki, T., Ishizaki, Y., 櫻井恵一, Nagafuchi, H., Matsumura, N., Uchida, M., Ando, T., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.05.007 · Cited by 26
Lippi, G., Sciacovelli, L., Trenti, T., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0038 · Cited by 22
Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms
Aksoyalp, Z. Ş., & Samur, D. N. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174548 · Cited by 27
D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 24
Jurdi, A. A., Gassen, R. B., Borges, T. J., Solhjou, Z., Hullekes, F. E., Lape, I. T., Efe, O., Alghamdi, A. S. A., Patel, P., Choi, J. Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838985 · Cited by 25
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 27
Pollock, K. M., Cheeseman, H. M., Szubert, A. J., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3859294 · Cited by 24
Approved delivery strategies for biopharmaceuticals
Zoulikha, M., Chen, Z., Wu, J., & He, W. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110225 · Cited by 28
Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
Xie, J., Feng, S., Li, X., Gea‐Mallorquí, E., Prats‐Uribe, A., & Prieto‐Alhambra, D. (2022) · Nature Communications · doi:10.1038/s41467-022-29159-x · Cited by 24
SARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 26
Zhou, J., Liu, Z., Zhang, G., Xu, W., Xing, L., Lu, L., Wang, Q., & Jiang, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28172 · Cited by 26
Fukuda, H., Maeda, M., & Murata, F. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.059 · Cited by 21
Chin, E. T., Leidner, D., Zhang, Y., Long, E., Prince, L., Schrag, S. J., Verani, J. R., Wiegand, R. E., Alarid‐Escudero, F., Goldhaber‐Fiebert, J. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1032 · Cited by 27
Jawalagatti, V., Kirthika, P., Hewawaduge, C., Yang, M., Park, J.-Y., Oh, B., & Lee, J. H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.042 · Cited by 24
The behavioral immune system and vaccination intentions during the coronavirus pandemic
Karlsson, L. C., Soveri, A., Lewandowsky, S., Karlsson, L., Karlsson, H., Nolvi, S., Karukivi, M., Lindfelt, M., & Antfolk, J. (2021) · Personality and Individual Differences · doi:10.1016/j.paid.2021.111295 · Cited by 24
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults
Formica, N., Mallory, R., Albert, G., Robinson, M., Plested, J. S., Cho, I., Robertson, A., Dubovsky, F., Glenn, G. M., & for the 2019nCoV-101 Study Group (2021) · doi:10.1101/2021.02.26.21252482 · Cited by 111
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 46
Pálinkás, A., & Sándor, J. (2022) · Vaccines · doi:10.3390/vaccines10071009 · Cited by 27
Ziegler, L., Klemis, V., Schmidt, T., Schneitler, S., Baum, C., Neumann, J., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104743 · Cited by 25
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 26
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
Lassaunière, R., Polacek, C., Gram, G. J., Frische, A., Tingstedt, J. L., Krüger, M., Dorner, B. G., Cook, A., Brown, R., Orekov, T., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00419-z · Cited by 26
Sun, S., Li, E., Zhao, G., Tang, J., Zuo, Q., Cai, L., Xu, C., Sui, C., Ou, Y., Liu, C., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121907 · Cited by 23
Madhi, S. A., Kwatra, G., Richardson, S. I., Koen, A. L., Baillie, V. L., Cutland, C., Fairlie, L., Padayachee, S. D., Dheda, K. U. J., Barnabas, S. L., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00596-5 · Cited by 27
Eosinophils as modulators of host defense during parasitic, fungal, bacterial, and viral infections
Gazzinelli-Guimarães, P. H., Jones, S. M., Voehringer, D., Mayer-Barber, K. D., & Samarasinghe, A. E. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae173 · Cited by 37
Sherman, A. C., Desjardins, M., Cheng, C., Bausk, B., Izaguirre, N., Zhou, G., Krauss, J., Tolan, N. V., Walt, D. R., Soiffer, R. J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab930 · Cited by 26
Self-citationMaeda, H., Saito, N., Igarashi, A., Ishida, M., Suami, K., Yagiuchi, A., Kimura, Y., Komino, M., Arai, H., Morikawa, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac292 · Cited by 24
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.